Bloom syndrome. (6th March 2014)

• Record Type: Journal Article
• Authors: Arora, Harleen; Chacon, Anna H.; Choudhary, Sonal; McLeod, Michael P.; Meshkov, Lauren; Nouri, Keyvan; Izakovic, Jan
• Is Part Of: International journal of dermatology. Volume 53:Number 7(2014:Jul.)
• Page Start: 798
• Page End: 802
• Publication Date: 2014-03-06
• Subjects: Dermatology -- Periodicals; 616.5
• DOI: 10.1111/ijd.12408
• Languages: English
• ISSNs: 0011-9059

Abstract

<abstract abstract-type="main" id="ijd12408-abs-0001"> <title>Abstract</title> <p>Bloom Syndrome (BS, MIM #210900) is an autosomal recessive genetic disorder caused by a mutation in the BLM gene, which codes for the DNA repair enzyme RecQL3 helicase. Without proper DNA repair mechanisms, abnormal DNA exchange takes place between sister chromatids and results in genetic instability that may lead to cancer, especially lymphoma and acute myelogenous leukemia, lower and upper gastrointestinal tract neoplasias, cutaneous tumors, and neoplasias in the genitalia and urinary tract. BS patients are usually of Ashkenazi Jewish descent and exhibit narrow facial features, elongated limbs, and several dermatologic complications including photosensitivity, poikiloderma, and telangiectatic erythema. The most concerning manifestation of BS is multiple malignancies, which require frequent screenings and strict vigilance by the physician. Therefore, distinguishing between BS and other dermatologic syndromes of similar presentation such as Rothmund–Thomson Syndrome, Erythropoietic Protoporphyria, and Cockayne Syndrome is paramount to disease management and to prolonging life. BS can be diagnosed through a variety of DNA sequencing methods, and genetic testing is available for high‐risk populations. This review consolidates several sources on BS sequelae and aims to suggest the importance of differentiating BS from other dermatologic conditions. This paper also elucidates the recently discovered BRAFT and FANCM protein complexes that link BS and Fanconi anemia.</p> </abstract>